Skip to main content

Towards a vaccine against helicobacter pylori

Objective

Studies in animal models have demonstrated prophylactic and therapeutic immunization against H. pylori, the causative agent of peptic ulcer and the major risk factor for gastric cancer. Vaccine candidates are in development and clinical trials are planned . The convolution of H. pylori with the human races has resulted in variation in strain genotype, immune response and disease progression which may compromise global vaccine efficacy. Here we address three fundamental questions relevant to a vaccine capable of conferring global protection :
1) Can antigens capable of conferring global protection against geographic strain variants be designed,
2) Can correlates of protection based on cytokine expression and immune system polarization be defined and
3) Will concurrent infection with strongly immune polarizing pathogens compromise vaccine efficacy. Parallel studies in Europe and in China, where over 80% of the population is infected, are planned.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

CHIRON S.R.L.
Address
Via Fiorentina 1
53100 Siena
Italy

Participants (3)

BEIJING MEDICAL UNIVERSITY
China
Address
Xizhimen Nei Street 11 People's Hospital
100012 Beijing
SECOND MILITARY MEDICAL UNIVERSITY
China
Address
174,Changhai Road 174 Changhai Hospital
200433 Shanghai
UNIVERSITY OF LEEDS
United Kingdom
Address
St. James's University Clinical Sciences Building
LS9 7TF Leeds